What Is a Medication-Assisted Treatment (MAT) Program?
Medication-Assisted Treatment (MAT) is an evidence-based approach to addiction treatment that combines FDA-approved medications with counseling and behavioral therapies. For individuals struggling with substance use disorders—especially opioid or alcohol dependence—MAT helps address both the physical and psychological aspects of addiction. Rather than relying on medication alone, MAT is designed to support recovery by stabilizing the body so meaningful therapeutic work can take place.
MAT programs are overseen by qualified medical professionals who receive specialized training in addiction medicine. These clinicians carefully evaluate each individual’s history, symptoms, and treatment goals to determine whether medication support is appropriate. When used correctly, MAT can reduce withdrawal discomfort, ease cravings, and significantly improve engagement in treatment—making recovery more attainable and sustainable.
Understanding How Medication-Assisted Treatment Works
The medications used in MAT help the body adjust during early recovery, when withdrawal symptoms and cravings are often at their most intense. These medications generally fall into three categories:
Agonists, which activate opioid receptors to reduce withdrawal symptoms
Partial agonists, which provide milder receptor activation without producing a full “high”
Antagonists, which block opioid receptors and prevent the rewarding effects
The specific medication used depends on the substance involved, medical history, and individual needs. MAT is always personalized and closely monitored to ensure safety and effectiveness.
Common Medications Used in MAT
Several medications are commonly used within MAT programs:
Buprenorphine (often prescribed as Subutex or Suboxone) is a partial opioid agonist that helps reduce cravings and withdrawal symptoms without producing euphoric effects. Approved by the FDA in 2002, it expanded access to treatment by allowing qualified physicians to prescribe it in outpatient settings.
Methadone is a long-acting opioid agonist that reduces cravings and blocks the effects of other opioids. It is administered under supervision and has been used for decades as a reliable option for individuals with severe opioid use disorder.
Naltrexone is a non-addictive opioid antagonist that blocks the euphoric and sedative effects of opioids. Available as an injection, nasal spray, or auto-injector, it does not cause dependence and is also used in alcohol addiction treatment.
How GLP-1 Is Changing Medication-Assisted Treatment for Addiction
Medication-assisted treatment (MAT) has come a long way since its early use in the mid-1900s, when medications like methadone were first introduced to manage opioid dependence. Today, drugs such as buprenorphine, methadone, and naltrexone are widely used and effective for many people with alcohol and opioid addiction. However, outcomes still vary based on the individual, the substance involved, and the underlying drivers of addiction, leaving significant gaps in treatment.
In recent years, researchers have begun studying new classes of medications that may address these gaps by targeting different brain regions and systems involved in addiction. Three promising categories include:
GLP-1 receptor agonists
Dopamine D3 receptor (D3R) antagonists
Corticotropin-releasing factor (CRF) antagonists
Early research suggests all three may help reduce cravings, substance use, or relapse risk in people with alcohol use disorder (AUD), opioid use disorder (OUD), and stimulant use disorder (StUD). It’s important to note that these findings come from a mix of animal studies and human research. While results are promising, further clinical trials are needed to better understand how these treatments work and how effective they are in real-world addiction care.
What Is GLP-1 and Why Does It Matter?
GLP-1 is a hormone naturally produced in the body and released mainly after eating. It helps regulate blood sugar by increasing insulin, lowering glucagon, slowing digestion, and reducing appetite. In short, GLP-1 tells the brain, “You don’t need more fuel right now.”
Because GLP-1 also reduces reward-driven eating, medications that activate GLP-1 signals without food intake can lower hunger cues and cravings. These medications have gained attention as breakthrough weight-loss drugs, though their original and primary role has been treating type 2 diabetes and obesity.
Researchers became interested in GLP-1s for addiction because GLP-1 receptors are found in brain areas that control dopamine, a chemical deeply involved in reward, motivation, and cravings. When GLP-1 receptors are activated in these areas, dopamine levels are reduced. They theorized that muting the “high” or rewarding effects of drugs and alcohol could reduce how compelling these substances feel, making cravings less intense and relapse less likely.
In short, GLP-1 medications may help reduce cravings and drug-seeking behavior by changing how the brain responds to addictive substances.
How the Research Was Conducted
The studies reviewed included laboratory animal models, clinical trials, large population studies, and real-world observational data. Animal studies helped identify how GLP-1 drugs affect reward and relapse pathways, while human studies examined alcohol use, relapse rates, and self-reported cravings over time.
Key Statistics From the GLP-1 Receptor Research
Several commonly prescribed GLP-1 medications, such as dulaglutide and semaglutide, have been examined in addiction-related research.
Alcohol Use Disorder (AUD)
Large population studies found a 38–46% lower risk of alcohol-related events in people taking GLP-1 medications within the first year.
In a clinical trial, patients taking dulaglutide drank 29% less alcohol over 12 weeks than those receiving a placebo.
Studies showed 50–56% lower rates of new or recurring AUD in obese patients using semaglutide compared to other weight-loss medications.
Analysis of over 68,000 online posts found 71% of users reported reduced alcohol cravings while taking GLP-1 drugs.
Opioid Use Disorder (early research)
In early laboratory studies using animal models that closely mimic human addiction patterns, GLP-1 medications reduced oxycodone and fentanyl use and drug-seeking behavior without affecting normal appetite or motivation for food.
Stimulant Use Disorder (early research)
In animal studies designed to mirror cocaine addiction and cravings, GLP-1 medications reduced cocaine use and drug-seeking behavior; however, research in humans is still limited and results remain mixed.
The Effectiveness of MAT
Research consistently shows that MAT improves treatment retention, reduces illicit drug use, lowers relapse risk, and decreases the spread of infectious diseases. When combined with therapy, accountability, and structured support—as it is in Renaissance Recovery’s outpatient programs—MAT becomes a powerful tool for long-term recovery, helping individuals regain stability, clarity, and confidence as they move forward.
Source
[1] https://www.imrpress.com/journal/JIN/24/4/10.31083/JIN26361
